A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction
NCT00437424
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Hepatocellular
Interventions
DRUG:
Brivanib
Sponsor
Bristol-Myers Squibb